



**SOUTH CAROLINA REVENUE AND FISCAL AFFAIRS OFFICE**  
**STATEMENT OF ESTIMATED FISCAL IMPACT**  
 (803)734-0640 • RFA.SC.GOV/IMPACTS

**Bill Number:** H. 4542  
**Author:** McKnight  
**Subject:** Experimental Health Care Treatment Law  
**Requestor:** House Medical, Military, Public, and Municipal Affairs  
**RFA Analyst(s):** Stein  
**Impact Date:** January 26, 2016

**Estimate of Fiscal Impact**

	<b>FY 2016-17</b>	<b>FY 2017-18</b>
<b>State Expenditure</b>		
General Fund	\$0	\$0
Other and Federal	\$0	\$0
Full-Time Equivalent Position(s)	0.00	0.00
<b>State Revenue</b>		
General Fund	\$0	\$0
Other and Federal	\$0	\$0
<b>Local Expenditure</b>	\$0	\$0
<b>Local Revenue</b>	\$0	\$0

**Fiscal Impact Summary**

This bill would have no expenditure impact on the General Fund, Federal Funds, or Other Funds.

**Explanation of Fiscal Impact**

**State Expenditure**

This bill amends Title 44 by adding Chapter 65 relating to Experimental Health Care Treatment. The bill establishes definitions and procedures by which a patient with an advanced (terminal) illness, upon a doctor's recommendation, may receive investigational drugs from a manufacturer. Insurers are not required to expand coverage to include such drugs and the cost of obtaining the drugs is solely the responsibility of the patient. However, manufacturers may provide the drug at no cost. The bill requires the patient to sign a consent form containing specified information and prohibits punitive actions against participants in these transactions.

The Department of Health and Environmental Control reports that this bill would have no expenditure impact on the General Fund, Federal Funds, or Other Funds.

**State Revenue**

N/A

**Local Expenditure**

N/A

**Local Revenue**

N/A

\_\_\_\_\_  
  
 Frank A. Rainwater, Executive Director